Roquinimex

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Roquinimex
Roquinimex.svg
Systematic (IUPAC) name
4-hydroxy-N,1-dimethyl-2-oxo-N-
phenyl-1,2-dihydroquinoline-3-carboxamide
Clinical data
Legal status ?
Pharmacokinetic data
Half-life 26-42 hours
Identifiers
CAS number 84088-42-6 YesY
ATC code L03AX02
PubChem CID 55197
ChemSpider 10619239 N
UNII 372T2944C0 YesY
Chemical data
Formula C18H16N2O3 
Mol. mass 308.331 g/mol
 N (what is this?)  (verify)

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.